Gun violence is surging — researchers finally have the money to ask why
With historically high levels of new funding, US gun-violence research is starting to find its footing.
The harrowing new reality for Alzheimer’s patients
Alzheimer’s patients and families live in a cloud of uncertainty. It’s about to get worse.
Dr. Beidas Advocates for Implementation Research and Mental Health Services in Congressional Briefing
Dr. Rinad Beidas was invited by the Friends of the National Institute of Mental Health (NIMH) coalition to participate in a congressional briefing to share information about mental health services and implementation research this July.
One Health-Care Company’s Audacious Plan to Lower Costs—and Still Turn a Profit
Oak Street says frequent checkups, meetings with social workers, and free rides can keep patients out of hospitals.
Top Tennessee Vaccine Official Says She Was Fired Over Shots for Teens
Michelle Fiscus, that state’s immunization leader, was only the latest state public health official to depart amid the pandemic.
FDA calls for federal investigation into its controversial Alzheimer’s drug approval
The head of the FDA has called for a wide-ranging federal investigation into the approval of Biogen’s treatment for Alzheimer’s disease just one month after a decision that sparked the ire of lawmakers, doctors, and public health advocates.
In Reversal, F.D.A. Calls for Limits on Who Gets Alzheimer’s Drug
Under fire for approving a questionable drug for all Alzheimer’s patients, the Food and Drug Administration greatly narrowed its previous recommendation and is now suggesting that only those with mild memory or thinking problems should receive it.
Is the Alzheimer’s Association really pushing Biogen to lower its new drug’s price — or is it lip service?
The Alzheimer’s Association stunned Washington last month when it urged Biogen to lower the price of its new Alzheimer’s drug — an extremely rare rebuke on drug pricing from a patient advocacy group, most of which normally sidestep the topic.
Racial differences in COVID mortality rates linked to unequal hospital quality, Penn study shows
Black, Hispanic, and Asian American communities are more likely to contract the coronavirus, to be hospitalized because of the virus, and to have an increased risk of death from the virus when compared to their white counterparts.
The new Alzheimer’s drug is the first of its kind. Will it be the last?
The FDA’s controversial approval of a Biogen drug for Alzheimer’s disease could blunt future R&D, experts warn.
Device Makers Have Funneled Billions to Orthopedic Surgeons Who Use Their Products
Medical industry payments to orthopedists and neurosurgeons who operate on the spine have risen sharply, despite government accusations that some of these transactions may violate federal anti-kickback laws, drive up health care spending and put patients at risk of serious harm, a KHN investigation has found.
Supreme Court dismisses challenge to Affordable Care Act, leaving it in place
The Supreme Court dismissed a challenge to the Affordable Care Act on Thursday in a decision that will leave the law intact and save health care coverage for millions of Americans.
Dr. Venkataramani Wins Milbank Quarterly Early Career Award in Population Health
Congratulations to Atheendar Venkataramani, MD, PhD, for receiving the 2021 Milbank Quarterly Early Career Award from the Interdisciplinary Association for Population Health Science.
Philadelphia Launches Philly Vax Sweepstakes
Members of our department helped Philadelphia launch the Philly Vax Sweepstakes, an incentive program to help boost COVID-19 vaccination rates among Philadelphia residents.
Penn dementia expert on newly approved Alzheimer’s drug: ‘The data aren’t strong enough’
Well before the FDA approved aducanumab, the first new Alzheimer’s drug since 2003, many dementia experts were lining up to criticize the monoclonal antibody. Jason Karlawish, co-director of the Penn Memory Center, was among them.
If the FDA approves Biogen’s Alzheimer’s treatment, I won’t prescribe it
From Jason Karlawish: Colleagues of mine in the Alzheimer’s sphere are also reluctant about approving aducanumab. Why? Biogen hasn’t made a convincing case for it.
Drug to Delay T1D Gets Tepid Endorsement by FDA Advisors
Teplizumab got a reticent thumbs-up from FDA advisors for an indication in delaying progression of at-risk patients to clinical type 1 diabetes (T1D).
Changing patterns and behaviors to improve mental health
As the world inches past the pandemic and things open up more, many people have vowed to make changes in their life, to get healthier, make a career change, or to create new social connections.
University of Pennsylvania Health System makes rare move to require COVID-19 vaccines for employees
The University of Pennsylvania Health System wants “to set an example for those who remain hesitant” by requiring employees to be vaccinated against COVID-19 by Sept 1.